SIGNIFICANT PHASE III CIMZIA RESULTS IN RHEUMATOID ARTHRITIS

Biotech Business Group

首页> 外文期刊>Biotech Business >SIGNIFICANT PHASE III CIMZIA RESULTS IN RHEUMATOID ARTHRITIS

【24h】

SIGNIFICANT PHASE III CIMZIA RESULTS IN RHEUMATOID ARTHRITIS

机译：类风湿关节炎的重大III期CIMZIA结果

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

UCB,Atlanta,has announced key results of a Phase III study(RAPID 1)involving nearly 1,000 patients on CIMZIA(TM)(certolizumab pegol),the first PEGylated,Fc-free anti-TNF,intended for the treatment of moderate to severe rheumatoid arthritis(RA).RAPID l's radiographic data showed that CIMZIA(TM)in combination with methotrexate prevented structural damage of the joints to a significantly greater degree than placebo plus methotrexate after one year of treatment.

机译：亚特兰大UCB宣布了一项III期研究的关键结果（RAPID 1），该研究涉及近1,000名患者使用CIMZIA（TM）（certolizumab pegol），这是首款PEG化，不含Fc的抗TNF药物，旨在治疗中重度类风湿关节炎（RA）。RAPIDl的射线照相数据显示，与安慰剂加甲氨蝶呤相比，CIMZIA（TM）与甲氨蝶呤的组合在治疗一年后可显着更大程度地防止关节的结构损伤。

著录项

来源
《Biotech Business》 |2007年第4期|共5页
作者
Biotech Business Group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类生物工程学（生物技术）;
关键词

相似文献

外文文献
中文文献
专利

1. SIGNIFICANT PHASE III CIMZIA RESULTS IN RHEUMATOID ARTHRITIS [J] . Biotech Business Group Biotech Business . 2007,第4期

机译：类风湿关节炎的重大III期CIMZIA结果
2. Golimumab, a Human Anti-Tumor Necrosis Factor alpha Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis (vol 60, pg 2272, 2009) [J] . Emery Arthritis and Rheumatism . 2010,第9期

机译：Golimumab是一种人类抗肿瘤坏死因子α单克隆抗体，每四周一次皮下注射纯净甲氨蝶呤的活动性类风湿性关节炎患者，III期，多中心，随机，双盲，安慰剂对照研究的二十四周结果甲氨tre呤之前戈利木单抗作为早期治疗类风湿关节炎的一线治疗方法的研究（第60卷，第2272页，2009年）
3. Golimumab, a Human Anti-Tumor Necrosis Factor alpha Monoclonal Antibody, Injected Subcutaneously Every Four Weeks in Methotrexate-Naive Patients With Active Rheumatoid Arthritis Twenty-Four-Week Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Golimumab Before Methotrexate as First-Line Therapy for Early-Onset Rheumatoid Arthritis (vol 60, pg 2272, 2009) [J] . Emery Arthritis and Rheumatism . 2010,第9期

机译：Golimumab是一种人类抗肿瘤坏死因子α单克隆抗体，每四周一次皮下注射纯净甲氨蝶呤的活动性类风湿性关节炎患者，III期，多中心，随机，双盲，安慰剂对照研究的二十四周结果甲氨tre呤之前戈利木单抗作为早期治疗类风湿关节炎的一线治疗方法的研究（第60卷，第2272页，2009年）
4. RHEUMATOID FACTOR-CORRELATED PROTEINS IS COMPLEMENTARY BIOMARKER OF RHEUMATOID ARTHRITIS [C] . Hee-Gyoo Kang, Sora Mun, Arum Park, International Mass Spectrometry Conference . 2018

机译：类风湿因子相关蛋白是类风湿性关节炎的互补生物标志物
5. Rheumatoid arthritis and osteoarthritis synovial fibroblasts express FcalphaR (CD89) in vitro and in vivo: Implications for rheumatoid arthritis. [D] . Wover, Roberta Michelle Antoinette. 2006

机译：类风湿关节炎和骨关节炎滑膜成纤维细胞在体外和体内表达FcalphaR（CD89）：对类风湿关节炎的影响。
6. Exposure–Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection [O] . Mohamed‐Eslam F. Mohamed, Ben Klünder, Heidi S. Camp, -1

机译：类风湿性关节炎II期试验中Upadacitinib疗效的暴露-反应分析及III期剂量选择的依据
7. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis : twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. [O] . Emery, Paul, Fleischmann, Roy M, Moreland, Larry W, 2009

机译：Golimumab是一种人类抗肿瘤坏死因子α单克隆抗体，每4周一次向未接受甲氨蝶呤治疗的活动性类风湿关节炎患者皮下注射：III期，多中心，随机，双盲，安慰剂对照的24周结果甲氨蝶呤前戈利木单抗作为早期治疗类风湿关节炎的一线治疗的研究。

SIGNIFICANT PHASE III CIMZIA RESULTS IN RHEUMATOID ARTHRITIS

摘要

著录项

相似文献

相关主题

期刊订阅